Arikayce liposomal is an antibiotic for treating adults with a lung infection caused by Mycobacterium avium complex (MAC), a group of bacteria commonly found in the environment, such as in soil and water. It is used in patients with limited treatment options who do not have cystic fibrosis. Lung infection caused by MAC is rare, and Arikayce liposomal was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 8 April 2014. Arikayce liposomal contains the active substance amikacin.
Therapeutic Indication
### Therapeutic indication Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
Therapeutic Area (MeSH)
ATC Code
J01GB06
ATC Item
amikacin
Pharmacotherapeutic Group
Antibacterials for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| amikacin sulfate | N/A | 阿米卡星 |
EMA Name
Arikayce liposomal
Medicine Name
Arikayce liposomal
Aliases
N/ANo risk management plan link.
